Source: VIP Gloves
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • VIP Gloves (VIP) receives Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves
  • The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia
  • This news follows USA Food and Drug Administration and European Union CE Mark approvals
  • VIP is up 7.50 per cent and is trading at 4.3 cents per share at 2:25 pm AEST

VIP Gloves (VIP) has received Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves.

Nitrile gloves are a synthetic rubber compound as opposed to latex.

The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia.

This news follows USA Food and Drug Administration and European Union CE Mark approvals.

Chairman Joe Wong is pleased to have secured TGA approval.

“We have been advancing distribution agreements for the Australian
market in recent months and, with TGA accreditation now received, these
can be finalised enabling sales to commence in the coming months,” Dr Wong said.

“VIP Gloves continues to expand its international sales footprint to become
a global glove supplier, providing a platform to launch the company’s house
brands as capacity expands in the coming months when the additional two
production lines come online.”

VIP was up 7.50 per cent and was trading at 4.3 cents per share at 2:25 pm AEST.

vip by the numbers
More From The Market Online

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

EMVision Medical Devices has been awarded a $3 million grant the Australian government’s national CRC-P program.

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…